

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	Group Art Unit: N/A
)	
Se Hwan YANG et al.)	Examiner: N/A
)	
Serial No.: N/A (National phase of PCT/KR2004/002474))	Filed: Herewith
)	
For: METHOD FOR MASS PRODUCTION OF HUMAN)	Confirmation No.: N/A
FOLLICLE STIMULATING HORMONE)	

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are attached.

English Language Patent Document:

A1. U.S. 2001/0007757 A1, July 12, 2001

English Language Non-Patent Documents:

C1. MANNAERTS et al., "Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle-stimulating hormone," <i>Endocrinology</i> , 129:2623-2630 (1991) (Abstract only)
C2. LOUMAYE et al., "Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility," <i>Human Reproduction Update</i> 4(6):862-881 (1998)
C3. OLIJVE et al., "Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®)," <i>Molecular Human Reproduction</i> , 2(5):371-382 (1996)
C4. GEBERT and GRAY, "Expression of FSH in CHO cells, I. Comparison of promoter types and effects of their respective inducers," <i>Cytotechnology</i> , 14:39-45 (1994)
C5. KEENE et al., "Expression of Biologically Active Human Follitropin in Chinese Hamster Ovary Cells," <i>Journal of Biological Chemistry</i> , 264(9):4769-4775 (1989)

It is respectfully requested that the Examiner indicate consideration of the cited references by returning copies of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

The present application is a national stage of international application number PCT/KR2004/002474, filed September 24, 2004 and copies of the published application (Publication Number, WO 2005/030969 A1) and the International Search Report are attached herewith.

The Commissioner is hereby authorized to charge JHK Law's Deposit Account No. **502486** for such fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. **502486**.

Respectfully submitted,

March 22, 2006
Date

/Joseph Hyosuk Kim/
Joseph Hyosuk Kim, Ph.D.
Reg. No. 41,425
Attorney for Applicants

JHK Law
P.O. Box 1078
La Canada, CA 91012-1078
Telephone: (818) 249-8177
Facsimile: (818) 249-8277

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT***(Use as many sheets as necessary)***Complete if Known**

Application Number	National phase of PCT/KR2004/002474
Filing Date	Herewith
First Named Inventor	YANG, Se Hwan
Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	58049-00025

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	MANNAERTS et al., "Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle-stimulating hormone," Endocrinology, 129:2623-2630 (1991) (Abstract only)	
	C2	LOUMAYE et al., "Recombinant follicle stimulating hormone: development of the first biotechnology product for the treatment of infertility," Human Reproduction Update 4(6):862-881 (1998)	
	C3	OLIJE et al., "Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®)," Molecular Human Reproduction, 2(5):371-382 (1996)	
	C4	GEBERT and GRAY, "Expression of FSH in CHO cells, I. Comparison of promoter types and effects of their respective inducers," Cytotechnology, 14:39-45 (1994)	
	C5	KEENE et al., "Expression of Biologically Active Human Follicle Stimulating Hormone in Chinese Hamster Ovary Cells," Journal of Biological Chemistry, 264(9):4769-4775 (1989)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	National Phase of PCT/KR2004/002474
Filing Date	Herewith
First Named Inventor	YANG, Se Hwan
Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	58049-00025

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.